Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > LATEST
LATEST
-
ARCHIVE JPMA Seminar on Innovation
April 30, 2007
-
ARCHIVE JPMA to Propose New Drug Pricing System in May
April 30, 2007
-
ARCHIVE Joint Consultation Services by PMDA, FDA, EMEA Suggested by Mr Nakagaki of Korosho
April 30, 2007
-
ARCHIVE REGULATORY NEWS IN BRIEF
April 30, 2007
-
COMMENTARY Explosion of Shin-Etsu Chemical's Cellulose Production PlantGood Opportunity to Reconsider Raw Material Procurement System
April 30, 2007
-
ARCHIVE Korosho Group Discusses Direct Contracts between Sponsors and Investigators
April 30, 2007
-
ARCHIVE Symposium
April 30, 2007
-
ARCHIVE R&D NEWS IN BRIEF
April 30, 2007
-
ARCHIVE India Featured at CPhi 2007
April 30, 2007
-
ARCHIVE Roche to Acquire BioVeris
April 30, 2007
-
ARCHIVE SymBio to Develop Bendamustine in Asia-Pacific Rim Countries
April 30, 2007
-
ARCHIVE MEDICAL DEVICE NEWS IN BRIEF
April 30, 2007
-
ARCHIVE BUSINESS NEWS IN BRIEF
April 30, 2007
-
ARCHIVE OINION:Times Are a Changin'
April 30, 2007
-
ARCHIVE NEW PRODUCTS
April 30, 2007
-
ARCHIVE Diabetes Care Should Be Standardized: Critical Path Seminar
April 30, 2007
-
ARCHIVE Zydus Acquires Nippon Universal
April 30, 2007
-
ARCHIVE Cancer Deaths Should Decrease by Half in Next 10 Years: Dr Kakizoe
April 30, 2007
-
ARCHIVE Generics to Be NHI Price-Listed Twice a Year from FY2007
April 30, 2007
-
ARCHIVE Korosho Study Group Issues GL on Terminal Care
April 30, 2007
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…